Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study - PubMed (original) (raw)
Clinical Trial
Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study
Seiji Niho et al. J Thorac Oncol. 2013 Jul.
Free article
Abstract
Introduction: We conducted a phase II study of combination chemotherapy with irinotecan (CPT) and cisplatin (CDDP) in patients with advanced large-cell neuroendocrine carcinoma (LCNEC) of the lung.
Methods: Patients received irinotecan (60 mg/m², days 1, 8, and 15) and cisplatin (60 mg/m², day 1) every 4 weeks for up to four cycles. The primary endpoint was the response rate. Expected and threshold values for the primary endpoint were 50% and 30%.
Results: Forty-four patients were enrolled between January 2005 and November 2011. The response rate (RR) was 54.5% (95% confidence interval [CI], 38.8-69.6%). The median progression-free survival time was 5.9 months (95% CI, 5.5-6.3), and the median survival time was 15.1 months (95% CI, 11.2-19.0). A central pathological review of specimens from 41 patients demonstrated that 30 patients had LCNEC but that 10 patients had small-cell lung cancer (SCLC) and one had non-small-cell lung cancer with a neuroendocrine structure. The RR was 46.7% (95% CI, 28.3-65.7%) in the LCNEC group and 80% (95% CI, 44.4-97.5%) in the SCLC group (p = 0.0823). The median survival time was 12.6 months (95% CI, 9.3-16.0) in the LCNEC group and 17.3 months (95% CI, 11.2-23.3) in the SCLC group (p = 0.047).
Conclusions: Combination chemotherapy with irinotecan and cisplatin was active in patients with LCNEC, but the RR and the overall survival period among the patients with LCNEC seemed to be inferior to those among the patients with SCLC. Small numbers of patients were a major limitation in this study.
Similar articles
- A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H, Niho S, Ito T, Ishikawa Y, Noguchi M, Tada H, Sekine I, Watanabe S, Yoshimura M, Yamamoto N, Oshita F, Kubota K, Nagai K. Kenmotsu H, et al. Lung Cancer. 2014 Jun;84(3):254-8. doi: 10.1016/j.lungcan.2014.03.007. Epub 2014 Mar 13. Lung Cancer. 2014. PMID: 24679951 Clinical Trial. - Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Zhang JT, Li Y, Yan LX, Zhu ZF, Dong XR, Chu Q, Wu L, Zhang HM, Xu CW, Lin G, Yu ZY, Hu J, Zhu B, Wang HJ, Yang F, Song ZB, Han ZB, Li MX, Lin J, Wu YL, Wang JL, Zhong WZ. Zhang JT, et al. Lung Cancer. 2020 Jan;139:118-123. doi: 10.1016/j.lungcan.2019.11.004. Epub 2019 Nov 11. Lung Cancer. 2020. PMID: 31775086 - Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?
Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK, Choi YS, Han J, Kim J, Kwon OJ, Shim YM, Park K. Sun JM, et al. Lung Cancer. 2012 Aug;77(2):365-70. doi: 10.1016/j.lungcan.2012.04.009. Epub 2012 May 11. Lung Cancer. 2012. PMID: 22579297 - Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Masuda N. Masuda N. Oncology (Williston Park). 2001 Jan;15(1 Suppl 1):13-8. Oncology (Williston Park). 2001. PMID: 11221016 Review. - Treatment of lung large cell neuroendocrine carcinoma.
Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Garassino MC. Lo Russo G, et al. Tumour Biol. 2016 Jun;37(6):7047-57. doi: 10.1007/s13277-016-5003-4. Epub 2016 Mar 4. Tumour Biol. 2016. PMID: 26943800 Review.
Cited by
- [Advances of Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma].
Sun J, Jing Y, Tian P, Li W, Li Y. Sun J, et al. Zhongguo Fei Ai Za Zhi. 2024 Aug 20;27(8):622-628. doi: 10.3779/j.issn.1009-3419.2024.102.28. Zhongguo Fei Ai Za Zhi. 2024. PMID: 39318255 Free PMC article. Review. Chinese. - Uncommon Metastasis of a Large-Cell Neuroendocrine Carcinoma From the Lungs to the Buccal Palatal Region.
Derfoufi J, Rezzoug F, El Jarroudi M, Nassira K, Al Jarroudi O, Brahmi SA, Afqir S. Derfoufi J, et al. Cureus. 2024 Aug 22;16(8):e67469. doi: 10.7759/cureus.67469. eCollection 2024 Aug. Cureus. 2024. PMID: 39310409 Free PMC article. - Combined large‑cell neuroendocrine carcinoma and small‑cell lung cancer: A case report.
Kong X, Yang J, Jiang Y. Kong X, et al. Oncol Lett. 2024 Aug 8;28(4):484. doi: 10.3892/ol.2024.14618. eCollection 2024 Oct. Oncol Lett. 2024. PMID: 39161337 Free PMC article. - Clinical and Pathologic Differences between Small-Cell Carcinoma and Large-Cell Neuroendocrine Carcinoma of the Lung.
Fujiwara W, Yotsukura M, Yoshida Y, Nakagawa K, Kashima J, Yatabe Y, Watanabe SI. Fujiwara W, et al. Ann Surg Oncol. 2024 Sep;31(9):5697-5705. doi: 10.1245/s10434-024-15505-4. Epub 2024 May 29. Ann Surg Oncol. 2024. PMID: 38811497 - Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.
Iida Y, Wakuda K, Kenmotsu H, Doshita K, Kodama H, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Ko R, Ono A, Naito T, Murakami H, Sugino T, Gon Y, Takahashi T. Iida Y, et al. Sci Rep. 2024 Apr 1;14(1):7641. doi: 10.1038/s41598-024-58327-w. Sci Rep. 2024. PMID: 38561461 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical